NYSE:ABT - Abbott Laboratories Stock Price, Forecast & News

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories announced a quarterly dividend on Friday, February 21st. Shareholders of record on Wednesday, April 15th will be given a dividend of $0.36 per share on Friday, May 15th. This represents a $1.44 annualized dividend and a yield of 1.82%. The ex-dividend date of this dividend is Tuesday, April 14th. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.08. View Abbott Laboratories' Dividend History.

Abbott Laboratories (NYSE:ABT) posted its earnings results on Wednesday, January, 22nd. The healthcare product maker reported $0.95 earnings per share for the quarter, meeting the consensus estimate of $0.95. The healthcare product maker had revenue of $8.31 billion for the quarter, compared to analysts' expectations of $8.26 billion. Abbott Laboratories had a net margin of 11.56% and a return on equity of 18.39%. The business's revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.81 EPS. View Abbott Laboratories' Earnings History.

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, April 15th 2020. View Earnings Estimates for Abbott Laboratories.

Abbott Laboratories issued an update on its FY20 earnings guidance on Wednesday, January, 22nd. The company provided earnings per share (EPS) guidance of $3.55-3.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.60.

18 equities research analysts have issued 12 month price targets for Abbott Laboratories' stock. Their forecasts range from $81.00 to $105.00. On average, they expect Abbott Laboratories' share price to reach $95.79 in the next twelve months. This suggests a possible upside of 21.0% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 2 sell ratings, 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.

News headlines about ABT stock have trended extremely negative on Thursday, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Abbott Laboratories earned a media sentiment score of -4.2 on InfoTrie's scale. They also gave news articles about the healthcare product maker a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Abbott Laboratories.

Some companies that are related to Abbott Laboratories include Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX), Varian Medical Systems (VAR) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Home Depot (HD), NVIDIA (NVDA), Walt Disney (DIS), Verizon Communications (VZ), Pfizer (PFE) and Intel (INTC).

Abbott Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (6.43%), State Street Corp (4.16%), Capital International Investors (2.68%), Massachusetts Financial Services Co. MA (1.75%), Geode Capital Management LLC (1.41%) and FMR LLC (1.41%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, FIL Ltd, FMR LLC, Thrivent Financial for Lutherans, Janus Henderson Group PLC, Massachusetts Financial Services Co. MA, Bank of New York Mellon Corp and UBS Asset Management Americas Inc.. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

ABT stock was acquired by a variety of institutional investors in the last quarter, including Polen Capital Management LLC, Wealth Quarterback LLC, Capital International Investors, State Street Corp, GQG Partners LLC, Capital Research Global Investors, Alliancebernstein L.P. and Milestone Resources Group Ltd. Company insiders that have bought Abbott Laboratories stock in the last two years include Daniel J Starks, John G Stratton and Randel William Woodgrift. View Insider Buying and Selling for Abbott Laboratories.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $79.19.

Abbott Laboratories has a market capitalization of $139.65 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 103,000 workers across the globe.View Additional Information About Abbott Laboratories.

The official website for Abbott Laboratories is http://www.abbott.com/.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.